Levi & Korsinsky, LLP Investigates SciClone Pharmaceuticals, Inc.
Levi & Korsinsky is investigating SciClone Pharmaceuticals, Inc. (“SciClone” or the “Company”) (NASDAQ:SCLN) for potentially violating state and federal securities laws by issuing false and misleading statements to its shareholders. Concerned shareholders should contact Joseph Levi at 877-363-5972 or by email at email@example.com for more information. All inquires will be kept in the strictest of confidence.
On August 9, 2010, SciClone revealed that the Securities and Exchange Commission has initiated a formal probe over certain business dealings in China. SciClone has also been contacted by the Department of Justice, which requested that the Company meet with them regarding its compliance with the Foreign Corrupt Practices Act (“FCPA”). On this news, shares of SciClone plunged 29% to $2.48. The FCPA prohibits a company from making illicit payments to foreign officials to obtain a business advantage.
If you purchased the common stock of SciClone and would like to discuss this action, or if you have any questions concerning your rights as a potential class member, please contact Joseph Levi either via email at firstname.lastname@example.org or by telephone at 877-363-5972, or visit http://www.zlk.com/sciclone-class-action.html.
Levi & Korsinsky has expertise in prosecuting investor securities
litigation and extensive experience in actions involving financial fraud
and represents investors throughout the nation, concentrating its
practice in securities and shareholder litigation.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV